Development of oral HSV-1 infection model in mice. Evaluation of efficacy of 5'-amino-5-iodo-2',5'-dideoxyuridine.
We developed a new model of oral HSV-1 infection in mice. After oral inoculation, 100 percent of mice developed the clinical lesions at the inoculated area and latent HVS infection in their trigeminal ganglia without mortality. The antiherpetic efficacy of AIdUrd, an agent specifically activated by herpesvirus-encoded enzyme, has been evaluated in this animal model. Early topical or systemic treatment of AIdUrd notably reduced the development of clinical lesions and the virus content in the inoculated lips. However, the establishment of latent HSV infection in the sensory ganglia was not influenced by AIdUrd treatment.
D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D007065:Idoxuridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008046:Lip / Q000382:microbiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018139:Simplexvirus / Q000302:isolation & purification; D013283:Stomatitis, Herpetic / Q000188:drug therapy* / Q000382:microbiology; D013997:Time Factors; D014276:Trigeminal Nerve / Q000382:microbiology
C021283:5'-amino-5-iodo-2',5'-dideoxyuridine; D007065:Idoxuridine